As somatic mutations in the cancer cells could contribute significantly to immune evasion and poor responses to therapies (Zacharakis et al., 2018), we proposed that the genomic changes of YTHDF2 might contribute to tumor development and progression, as well as influence the tumor therapy effects, partially through regulating immune reactions. The gene discussed is YTHDF2; the disease is neoplasm.